StemGen, Inc.
SGNI · OTC
3/31/2022 | 12/31/2021 | 9/30/2021 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.07 | 8.24 | 0.00 | -2.44 |
| FCF Yield | -0.13% | -0.04% | -0.10% | -0.02% |
| EV / EBITDA | -869.06 | -4,196.14 | -834.75 | -1,233.95 |
| Quality | ||||
| ROIC | 9.98% | 3.56% | 7.92% | 15.16% |
| Gross Margin | 0.00% | 35.80% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.78 | 0.50 | 0.48 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 36.68% | 29.52% | 27.51% | 59.58% |
| Free Cash Flow Growth | -257.12% | 38.58% | -590.85% | 75.27% |
| Safety | ||||
| Net Debt / EBITDA | -4.09 | -20.60 | -6.33 | -15.09 |
| Interest Coverage | -4.89 | -1.15 | -2.70 | -2.63 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,606.73 | -1,215.40 | 0.00 | -3,040.40 |